A clinic channel's short take on what tirzepatide does inside the body. No description came with it, so expect a general overview rather than new findings.
Recap by typeshit. Full story at Regenics Women's Health.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
Researchers say they found two approaches that may help limit weight gain once people stop GLP-1 treatment. The findings are at the link.
Venkat, who works as an ER physician, says dropping GLP-1 coverage for obesity only moves the cost to pricier medical problems later.
Loading…